Neuroblastoma epigenetics: From candidate gene approaches to genome-wide screenings

Epigenetics

Volumn 6, Issue 8, 2011, Pages 962-970

  Decock, Anneleen ^a   Ongenaert, Maté ^a   Vandesompele, Jo ^a   Speleman, Frank ^a  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

Author keywords

Apoptosis; Chromatin modification; Dna methylation; Epigenetics; Histone modifications; Neuroblastoma; Review

Indexed keywords

5 METHYLCYTOSINE ANTIBODY; ANTIBODY; APOPTOTIC PROTEASE ACTIVATING FACTOR 1; BINDING PROTEIN; BIOLOGICAL MARKER; CASPASE 8; CASPASE RECRUITMENT DOMAIN PROTEIN; DEATH RECEPTOR; DEATH RECEPTOR 4; DEATH RECEPTOR 5; DECOY RECEPTOR 2; DNA; NERVY AND DEAF 1 TYPE CONTAINING 10 PROTEIN; OSTEOPROTEGERIN; PROTEIN; PROTEIN PYCARD; RAS ASSOCIATION DOMAIN FAMILY PROTEIN 1A; RECEPTOR; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND RECEPTOR; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND RECEPTOR 3; UNCLASSIFIED DRUG;

ANALYTIC METHOD; APOPTOSIS; CHROMATIN IMMUNOPRECIPITATION; CLINICAL FEATURE; DNA METHYLATION; EPIGENETICS; EVENT FREE SURVIVAL; GENE EXPRESSION; GENETIC SCREENING; GENOME ANALYSIS; HUMAN; MICROARRAY ANALYSIS; MITOGENESIS; NEUROBLASTOMA; NONHUMAN; OVERALL SURVIVAL; PROGNOSIS; REVIEW; RISK FACTOR;

EID: 79961219036     PISSN: 15592294     EISSN: 15592308     Source Type: Journal    
DOI: 10.4161/epi.6.8.16516     Document Type: Review

References (44)

1. Berdasco M, Ropero S, Setien F, Fraga MF, Lapunzina P, Losson R, et al. Epigenetic inactivation of the Sotos overgrowth syndrome gene histone methyltransferase NSD1 in human neuroblastoma and glioma. P Natl Acad Sci USA 2009; 106:21830-5.
2. Sugino Y, Misawa A, Inoue J, Kitagawa M, Hosoi H, Sugimoto T, et al. Epigenetic silencing of prostaglandin E receptor 2 (PTGER2) is associated with progression of neuroblastomas. Oncogene 2007; 26:7401-13.
3. Teitz T, Wei T, Valentine MB, Vanin EF, Grenet J, Valentine VA, et al. Caspase 8 is deleted or silenced preferentially in childhood neuroblastomas with amplification of MYCN. Nat Med 2000; 6:529-35.
4. van Noesel MM, Versteeg R. Pediatric neuroblastomas: genetic and epigenetic "danse macabre." Gene 2004; 325:1-15.
5. Astuti D, Agathanggelou A, Honorio S, Dallol A, Martinsson T, Kogner P, et al. RASSF1A promoter region CpG island hypermethylation in phaeochromocytomas and neuroblastoma tumours. Oncogene 2001; 20:7573-7.
6. Elmore S. Apoptosis: a review of programmed cell death. Toxicol Pathol 2007; 35:495-516.
7. van Noesel MM, van Bezouw S, Salomons GS, Voûte PA, Pieters R, Baylin SB, et al. Tumor-specific downregulation of the tumor necrosis factor-related apoptosis- inducing ligand decoy receptors DcR1 and DcR2 is associated with dense promoter hypermethylation. Cancer Res 2002; 62:2157-61.
8. Ikegaki N, Katsumata M, Tsujimoto Y, Nakagawara A, Brodeur GM. Relationship between bcl-2 and myc gene expression in human neuroblastoma. Cancer Lett 1995; 91:161-8.
9. Ikeda H, Hirato J, Akami M, Matsuyama S, Suzuki N, Takahashi A, et al. Bcl-2 oncoprotein expression and apoptosis in neuroblastoma. J Pediatr Surg 1995; 30:805-8.
10. Castle VP, Heidelberger KP, Bromberg J, Ou X, Dole M, Nuñez G. Expression of the apoptosis-suppressing protein bcl-2, in neuroblastoma is associated with unfavorable histology and N-myc amplification. Am J Pathol 1993; 143:1543-50.
11. Alaminos M, Davalos V, Cheung NKV, Gerald WL, Esteller M. Clustering of gene hypermethylation associated with clinical risk groups in neuroblastoma. J Natl Cancer I 2004; 96:1208-19.
12. Grau E, Martinez F, Orellana C, Canete A, Yañez Y, Oltra S, et al. Hypermethylation of apoptotic genes as independent prognostic factor in neuroblastoma disease. Mol Carcinog 2010; 50:153-62.
13. Lazcoz P, Muñoz J, Nistal M, Pestaña A, Encío I, Castresana JS. Frequent promoter hypermethylation of RASSF1A and CASP8 in neuroblastoma. BMC Cancer 2006; 6:254.
14. Gonzalez-Gomez P, Bello MJ, Lomas J, Arjona D, Alonso ME, Amiñoso C, et al. Aberrant methylation of multiple genes in neuroblastic tumours relationship with MYCN amplification and allelic status at 1p. Eur J Cancer 2003; 39:1478-85.
15. Yang Q, Kiernan CM, Tian Y, Salwen HR, Chlenski A, Brumback BA, et al. Methylation of CASP8, DCR2 and HIN-1 in neuroblastoma is associated with poor outcome. Clin Cancer Res 2007; 13:3191-7.
16. Michalowski MB, de Fraipont F, Plantaz D, Michelland S, Combaret V, Favrot MC. Methylation of tumor-suppressor genes in neuroblastoma: The RASSF1A gene is almost always methylated in primary tumors. Pediatr Blood Cancer 2008; 50:29-32.
17. Hoebeeck J, Michels E, Pattyn F, Combaret V, Vermeulen J, Yigit N, et al. Aberrant methylation of candidate tumor suppressor genes in neuroblastoma. Cancer Lett 2009; 273:336-46.
18. Kamimatsuse A, Matsuura K, Moriya S, Fukuba I, Yamaoka H, Fukuda E, et al. Detection of CpG island hypermethylation of caspase-8 in neuroblastoma using an oligonucleotide array. Pediatr Blood Cancer 2009; 52:777-83.
19. Grau E, Martinez F, Orellana C, Canete A, Yañez Y, Oltra S, et al. Epigenetic alterations in disseminated neuroblastoma tumour cells: influence of TMS1 gene hypermethylation in relapse risk in NB patients. J Cancer Res Clin 2010; 136:1415-21.
20. Banelli B, Gelvi I, Di Vinci A, Scaruffi P, Casciano I, Allemanni G, et al. Distinct CpG methylation profiles characterize different clinical groups of neuroblastic tumors. Oncogene 2005; 24:5619-28.
21. Yagyu S, Gotoh T, Iehara T, Miyachi M, Katsumi Y, Tsubai-Shimizu S, et al. Circulating methylated-DCR2 gene in serum as an indicator of prognosis and therapeutic efficacy in patients with MYCN nonamplified neuroblastoma. Clin Cancer Res 2008; 14:7011-9.
22. Shahi MH, Schiapparelli P, Afzal M, Sinha S, Rey JA, Castresana JS. Expression and epigenetic modulation of sonic hedgehog-GLI1 pathway genes in neuroblastoma cell lines and tumors. Tumour Biol 2010; 32:113-27.
23. Ortiz-Vega S, Khokhlatchev A, Nedwidek M, Zhang X-feng, Dammann R, Pfeifer GP, et al. The putative tumor suppressor RASSF1A homodimerizes and heterodimerizes with the Ras-GTP binding protein Nore1. Oncogene 2002; 21:1381-90.
24. Rabizadeh S, Xavier RJ, Ishiguro K, Bernabeortiz J, Lopez-Ilasaca M, Khokhlatchev A, et al. The scaffold protein CNK1 interacts with the tumor suppressor RASSF1A and augments RASSF1A-induced cell death. J Biol Chem 2004; 279:29247-54.
25. Guo C, Tommasi S, Liu L, Yee JK, Dammann R, Pfeifer GP. RASSF1A is part of a complex similar to the Drosophila Hippo/Salvador/Lats tumor-suppressor network. Curr Biol 2007; 17:700-5.
26. Baksh S, Tommasi S, Fenton S, Yu VC, Martins LM, Pfeifer GP, et al. The tumor suppressor RASSF1A and MAP-1 link death receptor signaling to Bax conformational change and cell death. Mol Cell 2005; 18:637-50.
27. Agathanggelou A, Dallol A, Zöchbauer-Müller S, Morrissey C, Honorio S, Hesson L, et al. Epigenetic inactivation of the candidate 3p21.3 suppressor gene BLU in human cancers. Oncogene 2003; 22:1580-8.
28. Yang Q, Liu S, Tian Y, Hasan C, Kersey D, Salwen HR, et al. Methylation-associated silencing of the heat shock protein 47 gene in human neuroblastoma. Cancer Res 2004; 64:4531-8.
29. Misawa A, Tanaka S, Yagyu S, Tsuchiya K, Iehara T, Sugimoto T, et al. RASSF1A hypermethylation in pretreatment serum DNA of neuroblastoma patients: a prognostic marker. Brit J Cancer 2009; 100:399-404.
30. Schuebel KE, Chen W, Cope L, Glöckner SC, Suzuki H, Yi JM, et al. Comparing the DNA hypermethylome with gene mutations in human colorectal cancer. PLoS Genet 2007; 3:1709-23.
31. Margetts CDE, Morris M, Astuti D, Gentle DC, Cascon A, McRonald FE, et al. Evaluation of a functional epigenetic approach to identify promoter region methylation in phaeochromocytoma and neuroblastoma. Endocr-Relat Cancer 2008; 15:777-86.
32. Buckley PG, Das S, Bryan K, Watters KM, Alcock L, Koster J, et al. Genome-wide DNA methylation analysis of neuroblastic tumors reveals clinically relevant epigenetic events and large-scale epigenomic alterations localized to telomeric regions. Int J Cancer 2010; 128:2296-305.
33. Murphy DM, Buckley PG, Bryan K, Das S, Alcock L, Foley NH, et al. Global MYCN transcription factor binding analysis in neuroblastoma reveals association with distinct E-box motifs and regions of DNA hypermethylation. PloS One 2009; 4:8154.
34. Caren H, Djos A, Nethander M, Sjoberg RM, Kogner P, Enstrom C, et al. Identification of epigenetically regulated genes that predict patient outcome in neuroblastoma. BMC Cancer 2011; 11:66.
35. Lyko F, Foret S, Kucharski R, Wolf S, Falckenhayn C, Maleszka R. The Honey Bee Epigenomes: Differential Methylation of Brain DNA in Queens and Workers. PLoS Biol 2010; 8:1000506.
36. Cokus SJ, Feng S, Zhang X, Chen Z, Merriman B, Haudenschild CD, et al. Shotgun bisulphite sequencing of the Arabidopsis genome reveals DNA methylation patterning. Nature 2008; 452:215-9.
37. Serre D, Lee BH, Ting AH. MBD-isolated Genome Sequencing provides a high-throughput and comprehensive survey of DNA methylation in the human genome. Nucleic Acids Res 2010; 38:391-9.
38. Rauch T, Li H, Wu X, Pfeifer GP. MIRA-assisted microarray analysis, a new technology for the determination of DNA methylation patterns, identifies frequent methylation of homeodomain-containing genes in lung cancer cells. Cancer Res 2006; 66:7939-47.
39. Ruike Y, Imanaka Y, Sato F, Shimizu K, Tsujimoto G. Genome-wide analysis of aberrant methylation in human breast cancer cells using methyl-DNA immuno-precipitation combined with high-throughput sequencing. BMC genomics 2010; 11:137.
40. Yang Q, Zage P, Kagan D, Tian Y, Seshadri R, Salwen HR, et al. Association of epigenetic inactivation of RASSF1A with poor outcome in human neuroblastoma. Clin Cancer Res 2004; 10:8493-500.
41. Abe M, Ohira M, Kaneda A, Yagi Y, Yamamoto S, Kitano Y, et al. CpG island methylator phenotype is a strong determinant of poor prognosis in neuroblasto- mas. Cancer Res 2005; 65:828-34.
42. Alaminos M, Dávalos V, Ropero S, Setién F, Paz MF, Herranz M, et al. EMP3, a myelin-related gene located in the critical 19q13.3 region, is epigenetically silenced and exhibits features of a candidate tumor suppressor in glioma and neuroblastoma. Cancer Res 2005; 65:2565-71.
43. Misawa A, Inoue J, Sugino Y, Hosoi H, Sugimoto T, Hosoda F, et al. Methylation-associated silencing of the nuclear receptor 1I2 gene in advanced-type neuro-blastomas, identified by bacterial artificial chromosome array-based methylated CpG island amplification. Cancer Res 2005; 65:10233-42.
44. Banelli B, Bonassi S, Casciano I, Mazzocco K, Di Vinci A, Scaruffi P, et al. Outcome prediction and risk assessment by quantitative pyrosequencing methylation analysis of the SFN gene in advanced stage, high- risk, neuroblastic tumor patients. Int J Cancer 2010; 126:656-68.